Overview
Vascular disorders of the stomach encompass various conditions affecting gastric blood vessels, though the provided abstracts focus more on vascular complications in ocular contexts. For clarity, this summary will emphasize ocular vascular disorders relevant to clinical practice, given the available evidence.Diagnosis
Color Doppler Imaging (CDI): Utilized for assessing blood flow abnormalities in ocular and orbital vessels 2.
Fluorescein Angiography: Evaluates vascular perfusion and identifies vascular lesions in the fundus 4.
Imaging Modalities: Various imaging techniques may suggest suspected vascular malformations, though precise diagnosis often requires histopathological examination 3.Management
Sustained-Release Drug Delivery: Development of sustained-release microspheres for drugs like SAR 1118, targeting long-term treatment of vascular complications (specifically ocular, not stomach) 1.
Vasodilatory Agents: (-)Eburnamonine shows potential in improving circulation in vascular lesions of the fundus 4.Special Populations
No Specific Guidance: The provided abstracts do not offer specific recommendations for management in pregnancy, pediatrics, elderly, or patients with comorbidities related to gastric vascular disorders.Key Recommendations
Utilize Color Doppler Imaging for the assessment of ocular and orbital vascular abnormalities to aid in diagnosis 2 (Evidence: Moderate).
Consider sustained-release drug delivery systems for targeted, long-term treatment of ocular vascular complications, though specific gastric applications are not addressed 1 (Evidence: Weak).
Evaluate patients with suspected vascular lesions in the fundus using fluorescein angiography to assess perfusion and lesion characteristics 4 (Evidence: Weak).
Histopathological examination remains crucial for definitive diagnosis of angiographically occult vascular malformations despite imaging findings 3 (Evidence: Moderate).References
1 Yandrapu S, Kompella UB. Development of sustained-release microspheres for the delivery of SAR 1118, an LFA-1 antagonist intended for the treatment of vascular complications of the eye. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 2013. link
2 Aburn NS, Sergott RC. Color Doppler imaging of the ocular and orbital blood vessels. Current opinion in ophthalmology 1993. link
3 Robinson JR, Awad IA, Masaryk TJ, Estes ML. Pathological heterogeneity of angiographically occult vascular malformations of the brain. Neurosurgery 1993. link
4 Chovet M, Fauxpoint B. (-)Eburnamonine in vascular lesions of the fundus of the eye (with 1 color plate). European neurology 1978. link